Clinical Trials
Page 1 • 12 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease
Takeda announces positive topline results for TAK-881, showing pharmacokinetic comparability to HYQVIA in pivotal Phase 2/3 trial for PID patients.
Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026
Pulse Biosciences achieves 100% procedural success in atrial fibrillation treatment study with 95 evaluable patients at 6 months, presenting data at Heart Rhythm 2026.
SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026
SQ Innovation announces SUBCUT HF II trial results for Lasix ONYU, the first at-home subcutaneous furosemide treatment for heart failure edema, May 9th.
Krystal Biotech Reports Strong Q1 2026 Results with VYJUVEK Global Expansion and Two Registrational Studies Pending
Krystal Biotech announces Q1 2026 results highlighting VYJUVEK global expansion and two upcoming registrational study readouts for gene therapy pipeline.
Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026
Acurx presents promising data showing DNA pol IIIC inhibitors effectively treat MRSA infections while preserving gut microbiome, addressing key antibiotic concern.
GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment
GRIN Therapeutics initiates Phase 3 Beeline study in Europe for investigational radiprodil targeting GRIN-NDD, expanding global clinical program.
Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial
Oncolytics Biotech reports sustained clinical benefit with pelareorep immunotherapy in second-line RAS-mutant MSS colorectal cancer patients.
Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC
Nuvation Bio reports $18.5M Q1 2026 revenue for IBTROZI (taletrectinib) with majority of 200 new patients being TKI-naïve ROS1+ NSCLC cases.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations following a $7.4 billion settlement agreement. This landmark deal aims to address the company's role in the opioid crisis and provide compensation to victims.
Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis
Purdue Pharma, the maker of OxyContin, is set to dissolve after a judge approved its criminal sentence. This landmark decision is a significant development in the ongoing legal battles surrounding the opioid crisis.
Cerus Corporation INTERCEPT Blood System Advances Through European Regulatory Review and Phase 3 Trials
Cerus Corporation's INTERCEPT Blood System progresses through European regulatory review while Phase 3 RedeS trial readout and new INT200 device submission planned.
FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Metastatic Prostate Cancer
FDA's Oncologic Drugs Advisory Committee recognizes favorable benefit-risk profile for TRUQAP (capivasertib) in PTEN-deficient metastatic prostate cancer treatment.